Name: Medroxyprogesterone Acetate (MPA)
Brand: Selleck Chemicals
SKU: S2567
Availability: InStock
Rating: 5 (16 reviews)

Jump to

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	Adrenergic Receptor Estrogen/progestogen Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Opioid Receptor THR PGES
Featured Inhibitors	Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933

Solubility

In vitro
Batch:

DMSO : 12 mg/mL (31.04 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 12 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 30%PEG300 2 5%Tween80 3 60%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.500mg/ml (1.29mM)	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clarified DMSO stock solution to 300 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 600 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	386.52	Formula	C₂₄H₃₄O₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	71-58-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	NSC-26386, Medroxyprogesterone 17-acetate, Farlutin			SMILES	CC1CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	progestogen Receptor
In vitro	Medroxyprogesterone acetate (MPA) inhibits the enzyme 3-hydroxysteroid dehydrogenase, involved in the reversible conversion between 5alpha-dihydroprogesterone (DHP) and 3alpha, 5alpha-tetrahydroprogesterone (THP), and therefore may affect the local actions of DHP and THP in the brain. It reduces secretion of IL-6 and PTHrP from human breast cancer cells. This compound dose-dependently decreases the secretion and mRNA expression of IL-6 and PTHrP in the KTC-2 cells. MPA and dexamethasone dose dependently increase alpha-ENaC promoter-driven luciferase activity in M-1 cells, which is not inhibited by Org31710, indicating that it regulates alpha-ENaC in a PR-independent manner. This compound and dexamethasone, but not progesterone, dose dependently increase alpha-ENaC and sgk1 mRNA in M-1 and in Madin-Darby canine kidney-C7 cells, both collecting duct cell lines. At 0.1 nM, it significantly enhances the in vitro production of specific immunoglobulin G (IgG) antibodies, an effect that appears to involve the interaction of the progestin with PRG receptors
In vivo	Medroxyprogesterone acetate (MPA) impairs delayed memory retention on the water radial-arm maze (WRAM) and exacerbates overnight forgetting on the Morris maze (MM) in aged ovariectomized (OVX) rats. It significantly and progesterone marginally decreases GAD levels in the hippocampus, while both MPA and progesterone significantly increase GAD levels in the entorhinal cortex.
References	[1] https://pubmed.ncbi.nlm.nih.gov/16758493/ [2] https://pubmed.ncbi.nlm.nih.gov/12729473/ [3] https://pubmed.ncbi.nlm.nih.gov/16189295/ [4] https://pubmed.ncbi.nlm.nih.gov/11576224/ [5] https://pubmed.ncbi.nlm.nih.gov/20074654/ [6] https://pubmed.ncbi.nlm.nih.gov/33937078/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-31)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04877288	RECRUITING	Renal Allograft Recipients	Bristol-Myers Squibb	2021-07-21	PHASE3
NCT07462663	NOT_YET_RECRUITING	Endometrial Cancer; Endometrial Cancer Stage I; Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I; Atypical Endometrial Hyperplasia; Endometrial Intraepithelial Neoplasia; Obesity & Overweight; BMI>40; Obesity; Obesity Grade III	Hospital Universitari de Bellvitge	2027-01	PHASE4
NCT07488949	RECRUITING	Chronic Endometritis	Fang Wang	2024-04-09
NCT06942156	NOT_YET_RECRUITING	Heart Transplant	Chong Kun Dang Pharmaceutical	2025-08-14	PHASE4
NCT05255653	RECRUITING	Endometrial Cancer	Leiden University Medical Center	2021-11-11	PHASE2; PHASE3
NCT06549855	RECRUITING	Endometrial Cancer; Endometrioid Carcinoma; Mismatch Repair Deficiency	Peking University People's Hospital	2024-09-02

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Medroxyprogesterone Acetate (MPA) Progesterone Receptor Agonist

Chemical Structure

Molecular Weight: 386.52